AzurRx BioPharma Inc (NASDAQ:AZRX) has earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Brokers have set a twelve-month consensus target price of $8.83 for the company and are predicting that the company will post ($0.26) EPS for the current quarter, according to Zacks. Zacks has also given AzurRx BioPharma an industry rank of 185 out of 265 based on the ratings given to related companies.
Separately, HC Wainwright set a $8.00 price target on AzurRx BioPharma and gave the company a “buy” rating in a research note on Friday, January 19th.
AzurRx BioPharma stock traded down $0.13 during midday trading on Monday, reaching $3.01. The company’s stock had a trading volume of 18,131 shares, compared to its average volume of 49,823. AzurRx BioPharma has a 52-week low of $2.31 and a 52-week high of $5.25.
COPYRIGHT VIOLATION WARNING: “Zacks: AzurRx BioPharma Inc (AZRX) Receives Average Rating of “Strong Buy” from Analysts” was originally posted by WKRB News and is the property of of WKRB News. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.wkrb13.com/2018/04/02/zacks-azurrx-biopharma-inc-azrx-receives-average-rating-of-strong-buy-from-analysts.html.
AzurRx BioPharma Company Profile
AzurRx BioPharma, Inc is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.